NCT00621452 2014-08-06Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaFred Hutchinson Cancer CenterPhase 1 Completed12 enrolled